JOE
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Accepted Preprint first posted online on 3 June 2008

Journal of Endocrinology 2008;198:367.

Journal of Endocrinology (2008) In press
DOI: 10.1677/JOE-08-0113
© 2008 Society for Endocrinology
This Article
Right arrow Accepted manuscript (PDF)
Right arrow All Versions of this Article:
JOE-08-0113v1
198/2/367    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holmes, A.
Right arrow Articles by Febbraio, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holmes, A.
Right arrow Articles by Febbraio, M.

RESEARCH

Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPAR{alpha} and UCP2 expression in rats

Anna Holmes, Jose Mesa, Bronwyn Neill, Jason Chung, Andrew Carey, Gregory Steinberg, Bruce Kemp, Robert Southgate, Graeme Lancaster, Clinton Bruce, Matthew Watt and Mark Febbraio

A Holmes, Cellular and Molecular metabolism Laboratory, Diabetes & Metabolism Division, Baker Heart Research Institute, Melbourne, Australia
J Mesa, Cellular and Molecular metabolism Laboratory, Diabetes & Metabolism Division, Baker Heart Research Institute, Melbourne, Australia
B Neill, Cellular and Molecular metabolism Laboratory, Diabetes & Metabolism Division, Baker Heart Research Institute, Melbourne, Australia
J Chung, Cellular and Molecular metabolism Laboratory, Diabetes & Metabolism Division, Baker Heart Research Institute, Melbourne, Australia
A Carey, School of Medical Sciences, RMIT University, Bundoora, Australia
G Steinberg, St Vincent's Institute and Department of Medicine, University of Melbourne, Melbourne, Australia
B Kemp, St Vincent's Institute and Department of Medicine, University of Melbourne, Melbourne, Australia
R Southgate, Cellular and Molecular metabolism Laboratory, Diabetes & Metabolism Division, Baker Heart Research Institute, Melbourne, Australia
G Lancaster, Cellular and Molecular metabolism Laboratory, Diabetes & Metabolism Division, Baker Heart Research Institute, Melbourne, Australia
C Bruce, Cellular and Molecular metabolism Laboratory, Diabetes & Metabolism Division, Baker Heart Research Institute, Melbourne, Australia
M Watt, Department of Physiology,, Monash University, Clayton, Australia
M Febbraio, Cellular and Molecular metabolism Laboratory, Diabetes & Metabolism Division, Baker Heart Research Institute, Melbourne, Australia

Correspondence: Mark Febbraio, Email: mark.febbraio{at}baker.edu.au

Abstract

Chronic elevations in interleukin (IL)-6 have been associated with insulin resistance, but acute IL-6 administration can enhance insulin sensitivity. Our aim was to exogenously administer IL-6 to rats to elicit either chronic or repeated acute elevations in systemic IL-6. We hypothesized that a continuous elevation of IL-6 would inhibit glucose tolerance and insulin sensitivity while acute intermittent elevations would improve it. Male Wistar rats were treated for 14 d with recombinant human IL-6 (2.4 µg/day) or saline administered either by miniosmotic pump (Continuous IL-6) or via twice daily injection (Intermittent IL-6). Glucose and insulin tolerance tests were performed following 14 d treatment and 24 h later rats were administered a bolus of insulin (150 mU/g) or saline intraperitoneally. Approximately 10 min after insulin injection soleus, gastrocnemius and liver were excized and rapidly frozen in liquid nitrogen for subsequent metabolic measures. Irrespective of mode of delivery, IL-6 treatment increased basal insulin sensitivity, as measured by the homeostatic model assessment of insulin resistance, and enhanced glucose clearance during an intraperitoneal glucose tolerance test. IL-6 increased circulating fatty acids, but did not increase triglyceride accumulation in either skeletal muscle or liver, while it increased the protein expression of both PPAR{alpha} and UCP2 in skeletal muscle, suggesting that IL-6 can enhance fat oxidation via mitochondrial uncoupling. These data demonstrate that, irrespective of mode of delivery, IL-6 administration over 2 weeks enhances glucose tolerance. Our results do not support the notion that prolonged chronically elevated IL-6 impairs insulin action in vivo.




This article has been cited by other articles:


Home page
Exp PhysiolHome page
S. R. Gray, A. Ratkevicius, H. Wackerhage, P. Coats, and M. A. Nimmo
The effect of interleukin-6 and the interleukin-6 receptor on glucose transport in mouse skeletal muscle
Exp Physiol, August 1, 2009; 94(8): 899 - 905.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the Society for Endocrinology.